Questcor announced that the FDA has approved H.P. Acthar Gel (repository corticotropin injection) for the treatment of infantile spasms. Updated product labeling will now also include other indications for which Questcor believes Acthar may have therapeutic potential (eg, systemic lupus erythematosus, polymyositis, optic neuritis and others). The FDA did not require any post-approval commitments from Questcor for any of the indications on the revamped label beyond those related to the infantile spasms medication guide.
For more information call (800) 465-9217 or visit www.acthar.com.